TEM Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

62.490

Open

60.548

VWAP

60.47

Vol

4.10M

Mkt Cap

10.79B

Low

58.840

Amount

247.97M

EV/EBITDA(TTM)

Total Shares

179.56M

11.49B

EV/OCF(TTM)

P/S(TTM)

7.85

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

Events Timeline

(ET)

2026-06-26

14:00:00

Kalshi Plans New Funding Round Valued at $40 Billion

2026-06-25 (ET)

2026-06-25

09:01:00

Tempus AI Partners with Angiosarcoma Awareness to Advance Research

2026-06-11 (ET)

2026-06-11

09:00:00

Tempus AI Publishes Multi-Site Validation Study for Atrial Fibrillation Risk Prediction

2026-06-03 (ET)

2026-06-03

08:40:00

Tempus AI Launches Digital Pathology Open-Source Consortium with Yale New Haven Hospital

News

4.5

07-02NASDAQ.COM

Analysis of ARKK ETF's 52-Week Price Fluctuations

2.0

07-02stocktwits

Tempus AI Shareholder Sell-off Raises Market Concerns

8.0

06-25NASDAQ.COM

SoundThinking and SELLAS Options Trading Activity

7.5

06-25Newsfilter

Tempus AI Partners with Angiosarcoma Awareness to Advance Research

7.5

06-16Newsfilter

Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access

9.0

06-11Newsfilter

Tempus AI Receives FDA Clearance for Atrial Fibrillation Prediction Software

9 Analyst Rating

Wall Street analysts forecast TEM stock price to rise

4 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

76.00

Averages

84.38

High

105.00

Current: 0.000

Low

76.00

Averages

84.38

High

105.00

Freedom Capital

Gene Mannheimer

Hold

initiated

$59

AI Analysis

2026-06-30

Reason

Freedom Capital

Gene Mannheimer

Price Target

$59

AI Analysis

2026-06-30

initiated

Hold

Reason

Freedom Capital analyst Gene Mannheimer initiated coverage of Tempus AI with a Hold rating and $59 price target. Healthcare AI is one of the fastest-growing technology segments, says the analyst, who found that the majority of generative AI spend in healthcare is flowing to startups rather than large incumbent HCIT companies. Tempus AI has built one of the largest proprietary oncology data platforms and its positioning has the potential to put Tempus closer to the \"AI as physician\" thesis more than any other publicly traded healthcare technology company, the analyst tells investors. However, the firm believes it is still early innings for this theme to play out and believes valuation is \"about right,\" the analyst added.

Wolfe Research

Peer Perform

initiated

2026-06-01

Reason

Wolfe Research

Price Target

2026-06-01

initiated

Peer Perform

Reason

Wolfe Research assumed coverage of Tempus AI with a Peer Perform rating and no price target. The company's data offering is "differentiated" versus peers but lacks clarity around its long-term asset monetization, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEM

Unlock Now

Valuation Metrics

The current forward P/E ratio for Tempus AI Inc (TEM.O) is 0.00, compared to its 5-year average forward P/E of -97.78. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-97.78

Current PE

0.00

Overvalued PE

-43.08

Undervalued PE

-152.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

47.32

Current EV/EBITDA

-29.91

Overvalued EV/EBITDA

1377.87

Undervalued EV/EBITDA

-1283.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.67

Current PS

5.56

Overvalued PS

9.82

Undervalued PS

5.53

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks bearish tomorrow sell

Intellectia · 26 candidates

Relative Vol: >= 1.50Moving Average Relationship: PriceBelowMA5, PriceBelowMA20Is Optionable: TrueOne Day Rise Prob: <= 50.00One Day Predict Return: <= 0.0%Macd: bearish

Ticker

Name

Market Cap$

XPOF

Xponential Fitness Inc

320.79M

TNDM

Tandem Diabetes Care Inc

1.27B

TOST

Toast Inc

17.03B

TSSI

TSS Inc

457.15M

IRS

IRSA Inversiones y Representaciones SA

1.13B

TRDA

Entrada Therapeutics Inc

265.53M

stock pickers for today

Intellectia · 154 candidates

Market Cap: >= 2.00BVolume: >= 1,000,000Rsi Category: moderate, overboughtPrice Change Pct: $3.00 - $15.00Relative Vol: >= 1.50

Ticker

Name

Market Cap$

RGTI

Rigetti Computing Inc

5.03B

APLD

Applied Digital Corp

7.89B

HOOD

Robinhood Markets Inc

64.53B

BULL

Webull Corp

2.81B

AAL

American Airlines Group Inc

7.42B

WisdomTree Inc

2.32B

which bio stocks is declining

Intellectia · 12 candidates

Market Cap: >= 1000.00MSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchVolume: >= 500,000Price Change Pct: <= $-2.00Moving Average Relationship: PriceBelowMA20

Ticker

Name

Market Cap$

TEM

Tempus AI Inc

7.70B

IBRX

Immunitybio Inc

7.52B

PTGX

Protagonist Therapeutics Inc

6.31B

ADPT

Adaptive Biotechnologies Corp

1.97B

TYRA

Tyra Biosciences Inc

1.90B

GRAL

Grail Inc

1.87B

Whales Holding TEM

ARK Investment Management LLC

Catalytic Wealth RIA, LLC

Sanlam Investments Uk Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Tempus AI Inc (TEM) stock price today?

The current price of TEM is 60.09 USD — it has decreased -1

What is Tempus AI Inc (TEM)'s business?

What is the price predicton of TEM Stock?

Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is84.38 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.